Goker and Bhaman Analyze UK Biotech Scaling Challenges and Pension Capital Integration

Industry experts Hakan Goker of M Ventures and Maina Bhaman of Sofinnova Partners recently examined the current state of the United Kingdom’s biotechnology sector, focusing on the influence of the “Golden Triangle,” the difficulties of scaling domestic companies, and the integration of pension capital. The discussion highlights the structural challenges the UK faces in maintaining its global competitiveness within the life sciences investment ecosystem.

The analysis identifies the Golden Triangle—the region encompassing London, Oxford, and Cambridge—as a central, yet evolving, hub for biotech activity. Goker and Bhaman point to a disconnect between the region’s research output and the ability of firms to scale operations effectively. A primary focus of their assessment involves the potential role of UK pension funds, which remain a largely untapped source of capital for domestic biotech growth. By addressing these funding gaps and infrastructure hurdles, the experts suggest the sector aims to improve its position against international competitors.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 25, 2026

Author

GOAI